{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T07:44:55Z","timestamp":1782719095806,"version":"3.54.5"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T00:00:00Z","timestamp":1771718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003197","name":"Italian Medicines Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"AIRC Italian Association for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024370","name":"Ministero dell'Istruzione dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmogastro.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Gastrointestinal Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.esmogo.2026.100317","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T04:14:08Z","timestamp":1773893648000},"page":"100317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Effectiveness of FTD\/TPI plus bevacizumab and impact of prior bevacizumab exposure in patients with mCRC: the Italian FLOWER study"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9526-0725","authenticated-orcid":false,"given":"G.","family":"Trovato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2846-2517","authenticated-orcid":false,"given":"M.","family":"Carullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Nicastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Spoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Perissinotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Di Giacomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6856-2593","authenticated-orcid":false,"given":"M.A.","family":"Calegari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Pasquinucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Troiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Tamberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schirripa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Scartozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5306-3596","authenticated-orcid":false,"given":"F.","family":"Morano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0541-415X","authenticated-orcid":false,"given":"G.","family":"Arrivi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Basso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3789-5840","authenticated-orcid":false,"given":"M.","family":"Landi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8387-1968","authenticated-orcid":false,"given":"F.","family":"Zoratto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bergamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Landriscina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0262-535X","authenticated-orcid":false,"given":"J.","family":"Lucchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cremolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Tortora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3864-0719","authenticated-orcid":false,"given":"L.","family":"Salvatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmogo.2026.100317_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100317_bib2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.esmogo.2026.100317_bib3","first-page":"372","article-title":"Clinical management of metastatic colorectal cancer in the era of precision medicine","volume":"72","author":"Ciardiello","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.esmogo.2026.100317_bib4","first-page":"198","article-title":"Clinical updates for colon cancer care in 2022","volume":"21","author":"Fabregas","year":"2022","journal-title":"Clin Colorectal Cancer"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100317_bib5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41571-024-00965-0","article-title":"Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm","volume":"22","author":"Cirac\u00ec","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"20","key":"10.1016\/j.esmogo.2026.100317_bib6","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Eng J Med"},{"key":"10.1016\/j.esmogo.2026.100317_bib7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejca.2017.10.009","article-title":"The subgroups of the phase III RECOURSE trial of trifluridine\/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer","volume":"90","author":"Van Cutsem","year":"2018","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100317_bib8","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12876-024-03134-w","article-title":"Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a systematic review and meta-analysis","volume":"24","author":"Song","year":"2024","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.esmogo.2026.100317_bib9","first-page":"2135","article-title":"Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts","volume":"33","author":"Tsukihara","year":"2015","journal-title":"Oncol Rep"},{"key":"10.1016\/j.esmogo.2026.100317_bib10","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.3892\/or.2016.5208","article-title":"Effect of a novel oral chemotherapeutic agent containing a combination of trifluridine, tipiracil and the novel triple angiokinase inhibitor nintedanib, on human colorectal cancer xenografts","volume":"36","author":"Suzuki","year":"2016","journal-title":"Oncol Rep"},{"key":"10.1016\/j.esmogo.2026.100317_bib11","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine\u2013tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.esmogo.2026.100317_bib12","doi-asserted-by":"crossref","first-page":"e746","DOI":"10.1634\/theoncologist.2019-0647","article-title":"Real-world evidence in oncology: opportunities and limitations","volume":"25","author":"Di Maio","year":"2020","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.esmogo.2026.100317_bib13","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.annonc.2023.10.001","article-title":"ESMO Guidance for reporting oncology real-world evidence (GROW)","volume":"34","author":"Castelo-Branco","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmogo.2026.100317_bib14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmogo.2026.100317_bib15","year":"2017"},{"key":"10.1016\/j.esmogo.2026.100317_bib16","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.3390\/cancers12051187","article-title":"The relationship between ECOG-PS, mGPS, BMI\/WL grade and body composition and physical function in patients with advanced cancer","volume":"12","author":"Dolan","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmogo.2026.100317_bib17","first-page":"291","article-title":"Effects of palliative chemotherapy in unresectable or metastatic colorectal cancer patients with poor performance status","volume":"22","author":"Da Silva Rocha","year":"2023","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.esmogo.2026.100317_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100849","article-title":"New insights into antiangiogenic therapy resistance in cancer: mechanisms and therapeutic aspects","volume":"64","author":"Huang","year":"2022","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.esmogo.2026.100317_bib19","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1158\/0008-5472.CAN-04-0074","article-title":"Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors","volume":"64","author":"Tong","year":"2004","journal-title":"Cancer Res"},{"issue":"suppl 2","key":"10.1016\/j.esmogo.2026.100317_bib20","doi-asserted-by":"crossref","first-page":"S439","DOI":"10.1016\/j.annonc.2023.09.1804","article-title":"613P Effect of prior use of anti-VEGF agents on overall survival in patients with refractory metastatic colorectal cancer: a post-hoc analysis of the phase III SUNLIGHT trial","volume":"34","author":"Prager","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmogo.2026.100317_bib21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","article-title":"Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial","volume":"14","author":"Bennouna","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmogo.2026.100317_bib22","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/annonc\/mdv012","article-title":"Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial","volume":"26","author":"Masi","year":"2015","journal-title":"Ann Oncol"},{"issue":"suppl 2","key":"10.1016\/j.esmogo.2026.100317_bib23","doi-asserted-by":"crossref","first-page":"S440","DOI":"10.1016\/j.annonc.2023.09.1805","article-title":"614P Effect of KRASG12 mutations on overall survival in patients with refractory metastatic colorectal cancer: a post-hoc analysis of the phase III SUNLIGHT trial","volume":"34","author":"Tabernero","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmogo.2026.100317_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102945","article-title":"Impact of KRASG12 mutations on survival with trifluridine\/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer: post hoc analysis of the phase III SUNLIGHT trial","volume":"9","author":"Tabernero","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmogo.2026.100317_bib25","first-page":"342","article-title":"Trifluridine\/tipiracil in metastatic colorectal cancer: a UK multicenter real-world analysis on efficacy, safety, predictive and prognostic factors","volume":"20","author":"Stavraka","year":"2021","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.esmogo.2026.100317_bib26","doi-asserted-by":"crossref","first-page":"257","DOI":"10.6004\/jnccn.2022.7082","article-title":"A real-world comparison of regorafenib and trifluridine\/tipiracil in refractory metastatic colorectal cancer in the United States","volume":"21","author":"Nevala-Plagemann","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.esmogo.2026.100317_bib27","doi-asserted-by":"crossref","first-page":"976","DOI":"10.3390\/biomedicines13040976","article-title":"Real-world comparison of trifluridine-tipiracil with or without bevacizumab in patients with refractory metastatic colorectal cancer","volume":"13","author":"Kim","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.esmogo.2026.100317_bib28","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1080\/03007995.2018.1558851","article-title":"Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010 to 2016: a longitudinal assessment","volume":"35","author":"Weycker","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.esmogo.2026.100317_bib29","doi-asserted-by":"crossref","first-page":"S445","DOI":"10.1016\/j.annonc.2024.08.599","article-title":"530P Real-world effectiveness and predictive biomarker analysis of TAS-102+bevacizumab vs. regorafenib vs. TAS-102 in metastatic colorectal cancer: a multicenter cohort study","volume":"35","author":"Seeber","year":"2024","journal-title":"Ann Oncol"}],"container-title":["ESMO Gastrointestinal Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819826000178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819826000178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T06:52:17Z","timestamp":1782715937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949819826000178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":29,"alternative-id":["S2949819826000178"],"URL":"https:\/\/doi.org\/10.1016\/j.esmogo.2026.100317","relation":{},"ISSN":["2949-8198"],"issn-type":[{"value":"2949-8198","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of FTD\/TPI plus bevacizumab and impact of prior bevacizumab exposure in patients with mCRC: the Italian FLOWER study","name":"articletitle","label":"Article Title"},{"value":"ESMO Gastrointestinal Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmogo.2026.100317","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100317"}}